Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
44.27
+0.06 (0.14%)
May 27, 2026, 2:29 PM EDT - Market open
Veracyte Revenue
Veracyte had revenue of $139.07M in the quarter ending March 31, 2026, with 21.49% growth. This brings the company's revenue in the last twelve months to $541.74M, up 16.91% year-over-year. In the year 2025, Veracyte had annual revenue of $517.15M with 16.01% growth.
Revenue (ttm)
$541.74M
Revenue Growth
+16.91%
P/S Ratio
6.51
Revenue / Employee
$717,540
Employees
755
Market Cap
3.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 517.15M | 71.38M | 16.01% |
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.10B |
| Charles River Laboratories International | 4.03B |
| RadNet | 2.14B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 745.97M |
| GeneDx Holdings | 442.68M |
| Twist Bioscience | 409.48M |
VCYT News
- 7 hours ago - Veracyte genomic test identifies breast cancer patients who can skip chemo - Reuters
- 5 days ago - Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
- 5 days ago - OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
- 7 days ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 12 days ago - Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TheFly
- 12 days ago - Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - Business Wire
- 20 days ago - Veracyte price target raised to $42 from $40 at Canaccord - TheFly
- 20 days ago - Veracyte price target raised to $52 from $48 at UBS - TheFly